Previous 10 | Next 10 |
2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Updated data from over 60 patients showed consistent, deep and durable serum TTR reduction achieved with a single dose of NTLA-2001, including in 29 patients who have now reached 12 months or more of follow-up NTLA-2001 was generally well-tolerated across both polyneuropathy and cardiomyo...
Intellia Therapeutics Inc. (NTLA) is expected to report $-1.52 for Q3 2023
2023-10-31 12:46:31 ET More on Eli Lilly Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated Eli Lilly: Do Not Chase This Stock Over The Cliff ...
2023-10-28 07:30:00 ET When it comes to picking winning biotech companies, sometimes it pays to go with players who are at the cutting edge of their field. On Oct. 18, regulators at the Food and Drug Administration (FDA) confirmed that Intellia Therapeutics (NASDAQ: NTLA) is a leade...
New interim NTLA-2001 clinical data to be presented at the 4 th International ATTR Amyloidosis Meeting on November 2; data to include safety and both absolute and percent change in serum TTR reduction from cardiomyopathy and polyneuropathy arms of the study Intellia manageme...
2023-10-23 08:45:00 ET Cathie Woods, through her various ARK funds, has been scooping up shares of Intellia Therapeutics (NASDAQ: NTLA) , Block (NYSE: SQ) , and Ginkgo Bioworks (NYSE: DNA) lately. All three stocks have declined to start the year, but they have attrac...
2023-10-19 03:53:32 ET Summary ARK Invest's 13F portfolio value decreased by 14% to $13.07B this quarter. The top three holdings in the portfolio are Tesla, UiPath, and Coinbase Global. ARK Invest increased its stakes in Block, Twilio, Roblox, Ginkgo Bioworks Holdings, and Rob...
2023-10-18 07:45:24 ET More on Intellia, Regeneron, etc. Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global He...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice Pr...
2024-07-23 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...